Novel phosphodiesterase type 5 modulators: a patent survey (2008 – 2010)

Bibliography

• Kouvelas D. PDE5 inhibitors: in vitro and in vivo pharmacological profile. Curr Pharm Des 2009;15:3464-75
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs 2008;68:231-50
   PubMed Web of Science ®Google Scholar
• Guazzi M, Vicenzi M, Arena R, PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure/ clinical perspective. Circ Heart Fail 2011;4:8-17
   PubMed Web of Science ®Google Scholar
• Giovannoni MP, Vergelli C, Graziano A, PDE5 inhibitors and their applications. Curr Med Chem 2010;17:2564-87
   PubMed Web of Science ®Google Scholar
• Baek S-B, Bahn G, Moon S-J, The phosphodiesterase type-5 inhibitor, tadalafil, improves depressive symptoms, ameliorates memory impairment, as well as suppresses apoptosis and enhances cell proliferation in the hippocampus of maternal-separated rat pups. Neurosci Lett 2011;488:26-30
   PubMed Web of Science ®Google Scholar
• Bayer AG. PDE5 inhibitors for the treatment of hearing impairment. WO08151734; 2008
   Google Scholar
• Adamo CM, Dai D-F, Percival JM, Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2010;107:19079-83
   PubMed Web of Science ®Google Scholar
• University of Iowa Research Foundation. Inhibitors of phosphodiesterase type 5A for the treating or preventing muscle disease. WO10025266; 2010
   Google Scholar
• Koka S, Das A, Zhu S-G, Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther 2010;334:1023-30
   PubMed Web of Science ®Google Scholar
• Repub. Korean Kongkae Taeho Kongbo Pyrazolopyrimidinone compounds for treating coronary restenosis and for coating stents. KR09087795; 2009
   Google Scholar
• Choi SM, Shin JH, Kim JM, Effect of udenafil on portal venous pressure and hepatic fibrosis in rats. A novel therapeutic option for portal hypertension. Arzneimittelforschung 2009;59:641-6
   PubMedGoogle Scholar
• Kedia GT, Uckert S, Jonas U, The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 2008;26:603-9
   PubMed Web of Science ®Google Scholar
• Lubamba B, Lecourt H, Lebacq J, Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008;177:506-15
   PubMed Web of Science ®Google Scholar
• Lubamba B, Lebacq J, Reychler G, Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice. Eur Respir J 2011;37:72-8
   PubMed Web of Science ®Google Scholar
• Palmer MJ, Bell AS, Fox DNA, Design of second generation phosphodiesterase 5 inhibitors. Curr Top Med Chem 2007;7:405-15
   PubMedGoogle Scholar
• Surface Logix, Inc. Pharmacokinetically improved compounds. WO08024494; 2008
   Google Scholar
• CTG Pharma. New agents for the treatment of the low urinary tract dysfunctions. WO09037556; 2009
   Google Scholar
• Topharman Shanghai. Pyrazolopyrimidinone-containing Phenyl Guanidine derivatives. WO09097709; 2009
   Google Scholar
• Concert Pharmaceuticals 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-Propoxybenzenesulphonamide derivatives. US09197899; 2009
   Google Scholar
• Topharman Shanghai. Phenyl Pyrimidone Compounds. WO10066111; 2010
   Google Scholar
• Omori K, Mochida H, Fujishige K, Avanafil has the potential for the treatment of erectile dysfunction with selective phosphodiesterase-5. J Sex Med 2006;3(Suppl 3):221-2
   Google Scholar
• Peterson C, Swearingen D. Pharmacokinetics of avanafil, a new PDE5 inhibitor being developed for erectile dysfunction. J Sex Med 2006;3(Suppl 3):253-4
   PubMedGoogle Scholar
• Palmer MJ, Bell AS, Fox DNA, Brown DG. ORGN 582, Pyrazolopyrimidine PDE5 inhibitors – key learning from screen hit through to clinical candidate. 238th ACS National Meeting; Washington, DC; 2009
   Google Scholar
• Pfizer Pipeline. 2011. Available from: http://www.pfizer.com/research/product_pipeline/product_pipeline.jsp [Cited 28 2 2011]
   Google Scholar
• Pfizer Products, Inc. 1-(1-(2-Ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and salts thereof. WO07054778; 2007
   Google Scholar
• Choi H, Lee J, Kim YH, Discovery of potent, selective, and orally bioavailable PDE5 inhibitor: methyl-4-(3-chloro-4-methoxybenzylamino)-8-(2-hydroxyethyl)-7-methoxyquina zolin-6-ylmethylcarbamate (CKD 533). Bioorg Med Chem Lett 2010;20:383-6
   PubMed Web of Science ®Google Scholar
• Chong Kun Dang Pharmacuetical Corp. Quinazoline derivatives as phosphodiesterase inhibitor and a process for preparing the same. WO08020711; 2008
   Google Scholar
• Brass EP, Anthony R, Cobb FR, The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol 2006;48:2539-45
   PubMed Web of Science ®Google Scholar
• Hori M, Iwama T, Asakura Y, NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase 3 inhibitor, suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects. Eur J Pharmacol 2009;618:63-9
   PubMed Web of Science ®Google Scholar
• Qiu Y, Bhattacharjee S, Kraft P, JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction. Int J Impot Res 2006;18:477-83
   PubMed Web of Science ®Google Scholar
• Atir Holding. Heterocyclic compounds and uses thereof in the treatment of sexual disorders. WO07110868; 2007
   Google Scholar
• Auspex Pharmacueticals, Inc. Substituted PDE5 inhibitors. WO07146124; 2007
   Google Scholar
• Concert Pharmacueticals. Novel pharmaceutical compounds. WO07016361; 2007
   Google Scholar
• Nycomed GMBH. 6-Benzyl-2,3,4,7-tetrahydroindolo[2,3-c]quinoline compounds useful as PDE5 inhibitors. WO08095835; 2008
   Google Scholar
• Nycomed GMBH. Benzyl-substituted Tetracyclic Heterocyclic Compounds. WO10015588; 2010
   Google Scholar
• Nycomed GMBH. 5-Benzyl-1,2,3,6-Tetrahydro-4,6-Diaza-Cyclopenta[c]Fluorene Compounds and 5-Benzyl-1,2,3,6-Tetrahydro-4,6-Diaza-Cyclohepta[c]Fluorene Compounds. WO10015587; 2010
   Google Scholar
• Nycomed GMBH. 2,3,4,7-Tetrahydro-Indolo[2,3-c]Quinoline Compounds. WO10015586; 2010
   Google Scholar
• Nycomed GMBH. 6-Benzyl-2,3,4,7-Tetrahydro-Indolo[2,3-c]Quinoline Compounds. WO10015585; 2010
   Google Scholar
• Nycomed GMBH. Benzyl-substituted Tetracyclic Heterocyclic Compounds. WO11015523; 2011
   Google Scholar
• Nycomed GMBH. Pyrrolopyrimidinecarboxamides. WO09106531; 2009
   Google Scholar
• Nycomed GMBH. Methylpyrrolopyrimidinecarboxamides. WO11023693; 2011
   Google Scholar
• Nycomed GMBH. Methylpyrrolopyridinecarboxamides. WO11023693; 2011
   Google Scholar
• Hughes RO, Rogier DJ, Jacobsen EJ, Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant Inhibitor of phosphodiesterase 5 (PDE5). J Med Chem 2010;53:2656-60
   PubMedGoogle Scholar
• Pfizer Products, Inc. Pyridine[3,4-b]pyrazinones. WO07122466; 2007
   Google Scholar
• Pharmacia and Upjohn Co. LLC. Pyridopyrazinones as PDE-5 inhibitors. WO07020521; 2007
   Google Scholar
• Owen DR, Walker JK, Jon Jacobsen E, Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors. Bioorg Med Chem Lett 2009;19:4088-91
   PubMed Web of Science ®Google Scholar
• Pharmacia and Upjohn Co. LLC. Pyridine[2,3-b]pyrazinones. WO06126081; 2006
   Google Scholar
• Hughes RO, Walker JK, Cubbage JW, Investigation of aminopyridiopyrazinones as PDE5 inhibitors: evaluation of modifications to the central ring system. Bioorg Med Chem Lett 2009;19:4092-6
   PubMed Web of Science ®Google Scholar